Literature DB >> 26350342

Role of mesenchymal stem cell-derived fibrinolytic factor in tissue regeneration and cancer progression.

Beate Heissig1,2, Douaa Dhahri3, Salita Eiamboonsert3, Yousef Salama3, Hiroshi Shimazu4, Shinya Munakata4, Koichi Hattori4,5.   

Abstract

Tissue regeneration during wound healing or cancer growth and progression depends on the establishment of a cellular microenvironment. Mesenchymal stem cells (MSC) are part of this cellular microenvironment, where they functionally modulate cell homing, angiogenesis, and immune modulation. MSC recruitment involves detachment of these cells from their niche, and finally MSC migration into their preferred niches; the wounded area, the tumor bed, and the BM, just to name a few. During this recruitment phase, focal proteolysis disrupts the extracellular matrix (ECM) architecture, breaks cell-matrix interactions with receptors, and integrins, and causes the release of bioactive fragments from ECM molecules. MSC produce a broad array of proteases, promoting remodeling of the surrounding ECM through proteolytic mechanisms. The fibrinolytic system, with its main player plasmin, plays a crucial role in cell migration, growth factor bioavailability, and the regulation of other protease systems during inflammation, tissue regeneration, and cancer. Key components of the fibrinolytic cascade, including the urokinase plasminogen activator receptor (uPAR) and plasminogen activator inhibitor-1 (PAI-1), are expressed in MSC. This review will introduce general functional properties of the fibrinolytic system, which go beyond its known function of fibrin clot dissolution (fibrinolysis). We will focus on the role of the fibrinolytic system for MSC biology, summarizing our current understanding of the role of the fibrinolytic system for MSC recruitment and the functional consequences for tissue regeneration and cancer. Aspects of MSC origin, maintenance, and the mechanisms by which these cells contribute to altered protease activity in the microenvironment under normal and pathological conditions will also be discussed.

Entities:  

Keywords:  Cancer; Chemokine; Colorectal cancer; Hematopoiesis; Hypoxia; Integrin; MMP; Microenvironment; Niche; Plasmin; TGF-b; Tissue-type plasminogen activator; Wound healing; uPA; uPAR

Mesh:

Substances:

Year:  2015        PMID: 26350342     DOI: 10.1007/s00018-015-2035-7

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  131 in total

1.  Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin.

Authors:  D A Waltz; L R Natkin; R M Fujita; Y Wei; H A Chapman
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

2.  Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow.

Authors:  Yoshio Katayama; Michela Battista; Wei-Ming Kao; Andrés Hidalgo; Anna J Peired; Steven A Thomas; Paul S Frenette
Journal:  Cell       Date:  2006-01-27       Impact factor: 41.582

Review 3.  The adipocyte and hemostatic balance in obesity: studies of PAI-1.

Authors:  D J Loskutoff; F Samad
Journal:  Arterioscler Thromb Vasc Biol       Date:  1998-01       Impact factor: 8.311

4.  Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Implications of urokinase in colorectal carcinogenesis.

Authors:  C F Sier; H W Verspaget; G Griffioen; J H Verheijen; P H Quax; G Dooijewaard; P A De Bruin; C B Lamers
Journal:  Gastroenterology       Date:  1991-12       Impact factor: 22.682

5.  Human bone marrow-derived mesenchymal (stromal) progenitor cells (MPCs) cannot be recovered from peripheral blood progenitor cell collections.

Authors:  H M Lazarus; S E Haynesworth; S L Gerson; A I Caplan
Journal:  J Hematother       Date:  1997-10

6.  Tissue plasminogen activator is a potent activator of PDGF-CC.

Authors:  Linda Fredriksson; Hong Li; Christina Fieber; Xuri Li; Ulf Eriksson
Journal:  EMBO J       Date:  2004-09-16       Impact factor: 11.598

7.  Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1.

Authors:  Li-Jun Ma; Su-Li Mao; Kevin L Taylor; Talerngsak Kanjanabuch; YouFei Guan; YaHua Zhang; Nancy J Brown; Larry L Swift; Owen P McGuinness; David H Wasserman; Douglas E Vaughan; Agnes B Fogo
Journal:  Diabetes       Date:  2004-02       Impact factor: 9.461

8.  Convergence of the adhesive and fibrinolytic systems: recognition of urokinase by integrin alpha Mbeta 2 as well as by the urokinase receptor regulates cell adhesion and migration.

Authors:  Elzbieta Pluskota; Dmitry A Soloviev; Edward F Plow
Journal:  Blood       Date:  2002-09-26       Impact factor: 22.113

9.  Low-dose irradiation promotes tissue revascularization through VEGF release from mast cells and MMP-9-mediated progenitor cell mobilization.

Authors:  Beate Heissig; Shahin Rafii; Haruyo Akiyama; Yuichi Ohki; Yayoi Sato; Tejada Rafael; Zhenping Zhu; Daniel J Hicklin; Ko Okumura; Hideoki Ogawa; Zena Werb; Koichi Hattori
Journal:  J Exp Med       Date:  2005-09-12       Impact factor: 14.307

10.  Plasminogen activator inhibitor-1 is involved in streptozotocin-induced bone loss in female mice.

Authors:  Yukinori Tamura; Naoyuki Kawao; Kiyotaka Okada; Masato Yano; Katsumi Okumoto; Osamu Matsuo; Hiroshi Kaji
Journal:  Diabetes       Date:  2013-05-28       Impact factor: 9.461

View more
  16 in total

Review 1.  Role of Liposomes-Based Stem Cell for Multimodal Cancer Therapy.

Authors:  Pankaj Mandpe; Bala Prabhakar; Pravin Shende
Journal:  Stem Cell Rev Rep       Date:  2020-02       Impact factor: 5.739

2.  TCF7L2 promotes anoikis resistance and metastasis of gastric cancer by transcriptionally activating PLAUR.

Authors:  Tao Zhang; Bofang Wang; Fei Su; Baohong Gu; Lin Xiang; Lei Gao; Peng Zheng; Xue-Mei Li; Hao Chen
Journal:  Int J Biol Sci       Date:  2022-07-11       Impact factor: 10.750

3.  Deletion of Peroxiredoxin II Inhibits the Growth of Mouse Primary Mesenchymal Stem Cells Through Induction of the G0/G1 Cell-cycle Arrest and Activation of AKT/GSK3β/β-Catenin Signaling.

Authors:  Ying-Hao Han; Mei-Hua Jin; Ying-Hua Jin; Nan-Nan Yu; Jun Liu; Yong-Qing Zhang; Yu-Dong Cui; Ai-Guo Wang; Dong-Seok Lee; Sun-Uk Kim; Ji-Su Kim; Taeho Kwon; Hu-Nan Sun
Journal:  In Vivo       Date:  2020 Jan-Feb       Impact factor: 2.155

4.  Identification of Pathways in Liver Repair Potentially Targeted by Secretory Proteins from Human Mesenchymal Stem Cells.

Authors:  Sandra Winkler; Madlen Hempel; Sandra Brückner; Hans-Michael Tautenhahn; Roland Kaufmann; Bruno Christ
Journal:  Int J Mol Sci       Date:  2016-07-09       Impact factor: 5.923

5.  u-PAR expression in cancer associated fibroblast: new acquisitions in multiple myeloma progression.

Authors:  S Ciavarella; A Laurenzana; S De Summa; B Pilato; A Chillà; R Lacalamita; C Minoia; F Margheri; A Iacobazzi; A Rana; F Merchionne; G Fibbi; M Del Rosso; A Guarini; S Tommasi; S Serratì
Journal:  BMC Cancer       Date:  2017-03-24       Impact factor: 4.430

6.  In-vitro analysis of Quantum Molecular Resonance effects on human mesenchymal stromal cells.

Authors:  Sabrina Sella; Valentina Adami; Eliana Amati; Martina Bernardi; Katia Chieregato; Pamela Gatto; Martina Menarin; Alessandro Pozzato; Gianantonio Pozzato; Giuseppe Astori
Journal:  PLoS One       Date:  2018-01-02       Impact factor: 3.240

Review 7.  Stem cells as delivery vehicles for regenerative medicine-challenges and perspectives.

Authors:  Luminita Labusca; Dumitru Daniel Herea; Kaveh Mashayekhi
Journal:  World J Stem Cells       Date:  2018-05-26       Impact factor: 5.326

8.  Human mesenchymal stromal cells inhibit platelet activation and aggregation involving CD73-converted adenosine.

Authors:  P Netsch; S Elvers-Hornung; S Uhlig; H Klüter; V Huck; F Kirschhöfer; G Brenner-Weiß; K Janetzko; H Solz; P Wuchter; P Bugert; K Bieback
Journal:  Stem Cell Res Ther       Date:  2018-07-04       Impact factor: 6.832

Review 9.  Melatonin and Mesenchymal Stem Cells as a Key for Functional Integrity for Liver Cancer Treatment.

Authors:  Ehab Kotb Elmahallawy; Yasser Mohamed; Walied Abdo; Tokuma Yanai
Journal:  Int J Mol Sci       Date:  2020-06-25       Impact factor: 5.923

Review 10.  Mesenchymal Stem Cells after Polytrauma: Actor and Target.

Authors:  Markus Huber-Lang; Rebecca Wiegner; Lorenz Lampl; Rolf E Brenner
Journal:  Stem Cells Int       Date:  2016-06-02       Impact factor: 5.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.